الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 96 |  |  |
| | | from | 96 | | |
Abstract
The aim of the present study was the early diagnosis of atopic dermatitis by assessing role of EZH2. We also investigated the correlation between the serum level of EZH2 Atopic Dermatitis Patients in Suez Canal University Hospitals and Disease severity.
This was case control study, was carried out on patients presented to dermatology outpatient clinic of the Suez Canal University Hospitals, Ismailia with atopic dermatitis divide into 2 groups: (First group); included patients who had atopic dermatitis, (Second group); included healthy age and gender matched controls without any family history or previous history of clinical atopy symptoms. Severity of AD was evaluated using SCORAD. Blood samples were examined to detect: serum concentrations of EZH2.
The main results of the study revealed that:
In this study, 15(50%) patients were male and 15(50%) were female, and in the control group; 16(53.3%) were male and 14(46.7%) were female. The mean ± SD age of patients was 6.67 ± 3.39 years, while in the control group the mean ± SD age was 6.10 ± 3.92 years. There were insignificant difference between patients and controls as regard each of age and sex. The duration of the disease ranged from 1.0 to 12.0 years with a mean ± SD of 3.93± 3.36 years. 19 (63.3%) patients had family history of atopy, 24(80%) had history of allergy with 26(86.7%) had progressive course and 4(13.3%) had stationary course.
The scored ranged from 3.0 to 75.0 with a mean ± SD of 45.87 ± 20.88. Nine (30%) patients had moderate severity, and 18(60%) patients had severe form of AD.
Serum level of EZH2 in AD patients ranged from 6.83 – 13.12 pg/mL with a mean ± SD of 9.63 ± 1.38 pg/mL, and in the control group, ranged from 4.29 – 6.47 pg/mL with a mean ± SD of 5.19 ± 0.53 pg/mL. There was statistically significant difference between both groups as regarding EZH2 serum level which was higher in AD patients.
Serum level of EZH2 in patients with mild AD ranged from 6.83 – 7.33 pg/mL with a mean ± SD of 97.08 ± 0.25 pg/mL, moderate AD ranged from 8.01 – 9.70 pg/mL with a mean ± SD of 8.94 ± .55 pg/mL and in patients with severe AD, ranged from 8.51 – 13.12 pg/mL with a mean ± SD of 10.41 ± 1.03 pg/mL. There was statistically significant difference between serum EZH2 level and disease severity. Serum EZH2 had significant direct strong correlation with SCORAD. There were insignificant differences in serum EZH2 in gender, family history, course of disease and history of allergy.
Based on our finding we conclude that, EZH2 serum level was significantly higher in patients with AD than HCs. Thus, EZH2 may play a role in immune dysregulation encountered in AD and may be important predictor for AD severity.
This study uncovers the role of EZH2-dependent epigenetic modification in the regulation of AD keratinocyte hyperproliferation and clarifies the related mechanisms, providing new evidence for the involvement of histone methylation in the pathogenesis of AD. EZH2 is a potential molecular target for the treatment of AD and are worth attention in the future drug discovery for AD.
Recommendations
Further studies are recommended to investigate gene tissue expression of EZH2 in patients AD.
Further studies are recommended to assess serum level of EZH2 in patients AD before and after treatment modalities.
Further studies are recommended to investigate the correlation between serum level of EZH2 and other TH2 cytokines in AD patients.
References